Clinical Trials
10 trialsNCT04300556 2026-06-04
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Phase 1/2 Recruiting
NCT05024214 2026-03-25
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
3D Medicines
Phase 1/2 Recruiting
NCT03829332 2026-02-19
LEAP-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03976375 2025-08-15
LEAP-008
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04676412 2025-04-04
LEAP-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05620134 2024-10-15
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
Phase 1/2 Active not recruiting
NCT03006887 2021-05-20
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT01877083 2019-08-13
Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung
Eisai Inc.
Phase 2 Completed
NCT01529112 2017-09-26
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
Eisai Inc.
Phase 2 Completed
NCT00832819 2015-04-30
E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)
Eisai Inc.
Phase 1 Completed